AngioDynamics Announces Departure of CFO and Appointment of Interim CFO
October 22 2019 - 4:01PM
Business Wire
AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of
innovative, minimally invasive medical devices for vascular access,
peripheral vascular disease, and oncology, today announced that
Michael C. Greiner, Executive Vice President and Chief Financial
Officer (CFO) will be departing the Company. Stephen A. Trowbridge,
Senior Vice President and General Counsel, will assume the role of
interim Chief Financial Officer in addition to his current
responsibilities.
Mr. Greiner will remain with AngioDynamics to facilitate a
smooth transition of duties up to the filing of the second fiscal
quarter 10-Q, and the Company has initiated a process to determine
a permanent successor.
“We have made meaningful progress since Michael joined
AngioDynamics three years ago. We are a stronger company today, and
Michael has played an integral role in the transformation of our
portfolio, strengthening of our balance sheet and building a
talented and capable finance and accounting team,” said Jim
Clemmer, President and Chief Executive Officer of AngioDynamics,
Inc. “Completing the acquisition of Eximo Medical was a significant
milestone that offered us an opportunity to reflect on the
accomplishments of the past three years and evaluate our future.
Michael and I mutually agreed that now is the right time to bring a
new perspective to the organization as we enter our next phase of
execution. On behalf of the Board of Directors and everyone at
AngioDynamics, I want to thank Michael for all of his
contributions, and we wish him and his family all the best.”
Mr. Greiner's departure is unrelated to AngioDynamics’ business
performance, financial reporting, or controls.
The Company is reaffirming its previously issued financial
guidance for fiscal year 2020.
About AngioDynamics, Inc.
AngioDynamics, Inc. is a leading provider of innovative,
minimally invasive medical devices used by professional healthcare
providers for vascular access, peripheral vascular disease, and
oncology. AngioDynamics’ diverse product lines include
market-leading ablation systems, vascular access products,
angiographic products and accessories, drainage products,
thrombolytic products and venous products. For more information,
visit www.angiodynamics.com.
Safe Harbor
This release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
All statements regarding AngioDynamics' expected future financial
position, results of operations, cash flows, business strategy,
budgets, projected costs, capital expenditures, products,
competitive positions, growth opportunities, plans and objectives
of management for future operations, as well as statements that
include the words such as "expects," "reaffirms," "intends,"
"anticipates," "plans," "believes," "seeks," "estimates,"
"optimistic," or variations of such words and similar expressions,
are forward-looking statements. These forward-looking statements
are not guarantees of future performance and are subject to risks
and uncertainties. Investors are cautioned that actual events or
results may differ from AngioDynamics' expectations. Factors that
may affect the actual results achieved by AngioDynamics include,
without limitation, the ability of AngioDynamics to develop its
existing and new products, technological advances and patents
attained by competitors, infringement of AngioDynamics' technology
or assertions that AngioDynamics' technology infringes the
technology of fourth parties, the ability of AngioDynamics to
effectively compete against competitors that have substantially
greater resources, future actions by the FDA or other regulatory
agencies, domestic and foreign health care reforms and government
regulations, results of pending or future clinical trials, overall
economic conditions, the results of on-going litigation, challenges
with respect to fourth-party distributors or joint venture partners
or collaborators, the results of sales efforts, the effects of
product recalls and product liability claims, changes in key
personnel, the ability of AngioDynamics to execute on strategic
initiatives, the effects of economic, credit and capital market
conditions, general market conditions, market acceptance, foreign
currency exchange rate fluctuations, the effects on pricing from
group purchasing organizations and competition, the ability of
AngioDynamics to integrate acquired businesses, as well as the risk
factors listed from time to time in AngioDynamics' SEC filings,
including but not limited to its Annual Report on Form 10-K for the
year ended May 31, 2019. AngioDynamics does not assume any
obligation to publicly update or revise any forward-looking
statements for any reason.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191022006099/en/
Investor Relations: AngioDynamics, Inc. Stephen
Trowbridge 518-795-1408 strowbridge@angiodynamics.com
Media: AngioDynamics, Inc. Saleem Cheeks 518-795-1174
scheeks@angiodynamics.com
AngioDynamics (NASDAQ:ANGO)
Historical Stock Chart
From Mar 2024 to Apr 2024
AngioDynamics (NASDAQ:ANGO)
Historical Stock Chart
From Apr 2023 to Apr 2024